Publication Name	World Journal of Clinical Cases
Manuscript ID	88841
Country	China

Received	2023-11-06 09:24
Peer-Review Started	2023-11-06 09:24
To Make the First Decision
Return for Revision	2023-11-16 02:12
Revised	2023-11-22 00:32
Second Decision	2024-01-12 02:42
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-01-12 07:45
Articles in Press	2024-01-12 07:45
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-01-18 05:13
Publish the Manuscript Online	2024-01-25 08:28

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Case Report
Article Title	Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Jing-Hao Zhou, Qi-Jun Yi, Ming-Yan Li, Yan Xu, Qi Dong, Cong-Ying Wang and Hai-Yan Liu
ORCID	Author(s) ORCID Number Hai-Yan Liu http://orcid.org/0000-0002-6421-5516
Funding Agency and Grant Number	Funding Agency Grant Number the Science and Technology Innovation Development Project of Tai’an 2021NS160 the Medical and Health Science and Technology Development Plan of Shandong Province 202102010647
Corresponding Author	Hai-Yan Liu, MD, Doctor, Doctor, Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University, No. 706 Taishan Street, Tai’an 271000, Shandong Province, China. fylhy1998@163.com
Key Words	Inetetamab; Gastric cancer; Human epidermal growth factor receptor-2 protein; Tegafur; Case report
Core Tip	In this paper, we present a case involving a patient with human epidermal growth factor receptor-2 (HER2)-positive gastric cancer who was received oxaliplatin combined with tegafur as the first-line treatment post surgery. The patient was diagnosed with postoperative recurrence of gastric adenocarcinoma. He received inetetamab, an innovative domestically developed anti-HER2 monoclonal antibody, combined with tegafur chemotherapy as the second-line treatment. Evaluation of the efficacy of the second-line treatment revealed that the patient achieved a stable condition. This is significant because We provided a practical reference case for HER2-positive gastric cancer patients who was received inetetamab that is an innovative domestically developed anti-HER2 monoclonal antibody, which may help to provide survival benefits to some extent.
Publish Date	2024-01-25 08:28
Citation	Zhou JH, Yi QJ, Li MY, Xu Y, Dong Q, Wang CY, Liu HY. Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report. World J Clin Cases 2024; 12(4): 820-827
URL	https://www.wjgnet.com/2307-8960/full/v12/i4/820.htm
DOI	https://dx.doi.org/10.12998/wjcc.v12.i4.820

Full Article (PDF)	WJCC-12-820-with-cover.pdf
Full Article (Word)	WJCC-12-820.docx
CARE Checklist–2016	88841-CARE Checklist (2016).pdf
Manuscript File	88841_Auto_Edited-YJP.docx
Answering Reviewers	88841-Answering reviewers.pdf
Audio Core Tip	88841-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	88841-Conflict-of-interest statement.pdf
Copyright License Agreement	88841-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	88841-Grant application form(s).pdf
Signed Consent for Treatment Form(s) or Document(s)	88841-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	88841-Language certificate.pdf
Peer-review Report	88841-Peer-review(s).pdf
Scientific Misconduct Check	88841-Bing-Yan JP-2.png
Scientific Editor Work List	88841-Scientific editor work list.pdf
CrossCheck Report	88841-CrossCheck report.pdf